Protective efficacy of vaccines based on the Helicobacter suis urease subunit B and γ-glutamyl transpeptidase by Vermoote, Miet et al.
1 
 
Protective efficacy of vaccines based on the Helicobacter suis urease subunit B and γ–1 
glutamyl transpeptidase  2 
 3 
Miet Vermoote 
*
, Bram Flahou, Frank Pasmans, Richard Ducatelle, Freddy Haesebrouck 4 
Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, 5 
Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium 6 
* Corresponding author. Tel.:+32 9 264 73 61; fax: + 32 9 264 74 94. E-mail address: 7 
miet.vermoote@ugent.be (M. Vermoote) 8 
Co-authors email-addresses: 9 
BF: bram.flahou@ugent.be 10 
FP: frank.pasmans@ugent.be 11 
RD: richard.ducatelle@ugent.be 12 
FH: freddy.haesebrouck@ugent.be 13 
2 
 
Abstract 14 
Helicobacter (H.) suis causes gastric lesions in pigs and humans. This study aimed to evaluate 15 
the protective efficacy of immunization with combinations of the H. suis urease subunit B (UreB) 16 
and γ-glutamyl transpeptidase (GGT), both recombinantly expressed in Escherichia coli (rUreB 17 
and rGGT, respectively). Mice were intranasally immunized with rUreB, rGGT or a combination 18 
of both proteins, administered simultaneously or sequentially. Control groups consisted of non-19 
immunized and non-challenged mice (negative controls), sham-immunized and H. suis-20 
challenged mice (sham-immunized controls), and finally, H. suis whole-cell lysate-immunized 21 
and H. suis challenged mice. Cholera toxin was used as mucosal adjuvant. All immunizations 22 
induced a significant reduction of gastric H. suis colonization, which was least pronounced in the 23 
groups immunized with rGGT and rUreB only. Consecutive immunization with rGGT followed 24 
by rUreB and immunization with the bivalent vaccine improved the protective efficacy compared 25 
to immunization with single proteins, with a complete clearance of infection observed in 50% of 26 
the animals. Immunization with whole-cell lysate induced a similar reduction of gastric bacterial 27 
colonization compared to rGGT and rUreB in combinations. Gastric lesions, however, were less 28 
pronounced in mice immunized with combinations of rUreB and rGGT compared to mice 29 
immunized with whole-cell lysate. In conclusion, vaccination with a combination of rGGT and 30 
rUreB protected mice against a subsequent H. suis infection and was not associated with severe 31 
post-vaccination gastric inflammation, indicating that it may be a promising method for control 32 
of H. suis infections. 33 
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1. Introduction 36 
Helicobacter (H.) suis is a worldwide spread bacterium causing chronic gastritis and reduced 37 
daily weight gain in pigs [1]. An infection with H. suis has also been associated with erosive and 38 
ulcerative lesions in the non-glandular part of the porcine stomach [2,3]. Furthermore, this 39 
bacterium is the most prevalent non-H. pylori Helicobacter species colonizing the stomach of 40 
humans suffering from gastric disease [4]. Previous studies in mice have shown that prophylactic 41 
intranasal immunization with H. suis whole-cell lysate results in significant protection against H. 42 
suis infections [5,6]. However, production of sufficient H. suis whole-cell lysate may be hindered 43 
by the laborious in vitro cultivation of this bacterium. Also, whole-cell lysates may contain both 44 
protective antigens and antigens suppressing protection [7]. To overcome these drawbacks, a 45 
subunit vaccine, based on the H. suis urease subunit B (UreB) has been developed [6]. 46 
Immunization with H. suis UreB, recombinantly expressed in E. coli (rUreB) only induced a 47 
partial protection against H. suis challenge in a mouse model and it has been suggested that 48 
inclusion of additional antigens might improve the protective efficacy of this subunit vaccine [6]. 49 
In addition, immune modulating factors produced by the bacterium may hamper the development 50 
of a fully potent immune response against a H. suis infection, and thus may influence the 51 
effectiveness of certain vaccine formulations. Indeed, H. suis γ-glutamyl transpeptidase (GGT) 52 
has been shown to modulate the function of lymphocytes in vitro, which may result in host 53 
immune escape of H. suis leading to a chronic infection and lifelong persistence of H. suis in the 54 
porcine stomach [8]. Inhibition of this H. suis virulence factor by vaccination, may lead to an 55 
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abrogation of its immune modulatory effect, enabling the development of a fully potent immune 56 
response against H. suis infection. 57 
The aim of the present study was to evaluate the protective efficacy of simultaneous or 58 
consecutive immunization with recombinant H. suis GGT (rGGT) and rUreB against H. suis 59 
infections, and to compare it with that of H. suis lysate and univalent vaccination in a 60 
standardized mouse model. 61 
2. Materials and methods 62 
2.1. Bacterial strain 63 
H. suis strain 5 (HS5) was used in all experiments. This strain was isolated from the gastric 64 
mucosa of a sow, according to the method described by Baele et al. [9]. 65 
2.2. Antigens for immunization 66 
Recombinantly expressed GGT (rGGT) was prepared as described previously [10]. Briefly, HS5 67 
DNA was used as template to PCR-amplify the ggt gene without predicted signal sequence, 68 
cloned into the pENTR™/SD/D-TOPO® vector and transferred into the pDEST™17 destination 69 
vector. Chemically competent E.coli BL21-AI™ cells were transformed and protein expression 70 
was induced with 0.2% L-arabinose. rGGT was purified by (His)6-tag affinity on a Ni-sepharose 71 
column (His GraviTrap; GE Healthcare Bio-Sciences AB) following manufacturer’s instructions. 72 
For further purification, the rGGT was loaded on a Superdex 75 gel filtration column (GE 73 
Healthcare Bio-sciences AB). Afterwards, rGGT was analyzed using sodium dodecyl sulfate-74 
polyacrylamide gel electrophoresis (SDS-PAGE) and the GGT activity assay [12].  75 
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Recombinantly expressed UreB (rUreB) was prepared as described previously [6]. Briefly, a 76 
fragment encoding the HS5 UreB sequence was amplified by PCR and cloned into the protein 77 
expression vector pET-24d. The rUreB was expressed in E. coli strain BL21 (DE3) and E. coli 78 
cells were lyzed by sonication in a buffer containing 50mM Na.PO4 pH7, 0.5M NaCl, 1M DTT, 79 
1% Triton X-100 and 1mM PMSF. rUreB was purified using Ni-affinity chromatography in 80 
buffer consisting of 1 M NaCl, 50 mM PBS, 1% Triton X-100, 250 mM imidazole and 10% 81 
glycerol (His GraviTrap; GE Healthcare Bio-Sciences AB) followed by gel filtration on a 82 
Superdex™ 200 HR 16/60 column (GE Healthcare Bio-sciences AB). After purification, rUreB 83 
was analyzed using SDS-PAGE and Western-blot analysis using anti-hexahistidine-tag mouse 84 
monoclonal antibody (Icosagen Cell Factory, Tartu, Estonia). The detergent Triton X-100 was 85 
removed from the purified rUreB by using Pierce Detergent Removal Spin columns (Pierce 86 
Biotechnology, Rockford, USA) following manufacturer’s instructions. 87 
H. suis whole-cell lysate (lysate) was prepared as described by Flahou et al. [5], but without final 88 
filtration of the supernatant. The latter was done to prevent potential loss of antigens. Protein 89 
concentrations were determined with the RC DC protein Assay (Bio-Rad, Hercules, CA, USA). 90 
2.3. Immunization and infection experiments 91 
One week prior to the initiation of the experiments, 70 five-week-old specific-pathogen-free 92 
female BALB/c mice were obtained from an authorized breeder (HARLAN, Horst, The 93 
Netherlands). The animals were housed on autoclaved wood shavings in filter top cages. They 94 
were fed an autoclaved commercial diet (TEKLAD 2018S, HARLAN) and received autoclaved 95 
water ad libitum. All experiments involving animals were approved by the Animal Care and 96 
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Ethics Committee of the Faculty of Veterinary Medicine, Ghent University (EC2011/164). 97 
Immunization and infection experiments were performed as presented in Figure 1. Mice were 98 
divided over seven groups of 10 animals each. Groups 1, 2, 3, 5, 6 and 7 were intranasally 99 
inoculated twice with three weeks interval, with a total volume of 17.5 µl/ dose. In groups 1, 2, 3 100 
and 5, vaccine formulations consisted of Hank’s balanced salt solution (HBSS) with 5 µg cholera 101 
toxin (CT) (List Biological Laboratories Inc., Madison, NJ, USA), to which 30 µg rUreB, 30 µg 102 
rGGT, 30 µg rGGT + 30 µg rUreB, and 100 µg lysate had been added, respectively. Groups 6 103 
(sham-immunized group) and 7 (negative control group) received HBSS only. Mice from group 4 104 
were first immunized twice (with three weeks interval) with a vaccine consisting of HBSS, 5 µg 105 
CT and 30 µg rGGT. One week after the second immunization animals were immunized twice 106 
(with three weeks interval) with a vaccine consisting of HBSS, 5 µg CT and 30 µg rUreB. Three 107 
weeks after the last immunization, blood was collected by tail bleeding from five animals per 108 
group and one week later, all animals, except the negative control group, were intragastrically 109 
inoculated with 200 µL Brucella broth at pH 5 containing 10
8
 viable H. suis bacteria [11]. The 110 
negative control group was intragastrically inoculated with 200 µL Brucella broth at pH 5. Four 111 
weeks after the challenge with H. suis, mice were euthanized by cervical dislocation following 112 
isoflurane anaesthesia (IsoFlo; Abbott, IL, USA). Blood was collected by sterile cardiac 113 
puncture, centrifuged (1000 g, 4°C, 10 min) and serum was frozen at -70°C until further use. 114 
Stomachs were excised and dissected along the greater curvature. One-half of the stomachs, 115 
including antrum and fundus, was immediately placed into 1 mL RNA Later (Ambion, Austin, 116 
TE, USA) and stored at -70°C for further RNA- and DNA-extraction. A longitudinal strip of 117 
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gastric tissue was cut from the oesophagus to the duodenum along the greater curvature for 118 
histopathological examination. 119 
 120 
Figure 1. Experimental design of vaccination study. Per group 10 mice were intranasally 121 
immunized twice with 3 weeks interval, each time with 30 µg rUreB + 5 µg cholera toxin (CT), 122 
30 µg rGGT + 5 µg CT, 30 µg rGGT + 30 µg rUreB + 5 µg CT, and 100 µg lysate + 5 µg CT 123 
(groups 1, 2, 3 and 5, respectively). Groups 6 (sham-immunized group) and 7 (negative control 124 
group) were intranasally immunized with HBSS. Mice from group 4 (rGGT→rUreB) were first 125 
intranasally immunized twice with 3 weeks interval, each time with 30 µg rGGT and 5 µg CT. 126 
One week after the second immunization animals were immunized twice with 3 weeks interval 127 
with 30 µg rUreB + 5 µg CT. Three weeks after the last immunization, blood was collected by 128 
tail bleeding from 5 animals per group and one week later, all animals, except the negative 129 
control group, were intragastrically inoculated 10
8
 viable H. suis bacteria. The negative control 130 
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group was intragastrically inoculated with 200 µL Brucella broth at pH5. Four weeks after 131 
challenge with H. suis, mice were euthanized. 
a 
I (x): Immunization of (number of group). 132 
 133 
2.4. Determination of the number of H. suis in the stomach 134 
After thawing, stomach tissues were homogenized (MagNAlyser, Roche, Mannheim, Germany) 135 
in 1 mL Tri Reagent
®
 RT (MRC, Brunschwig Chemie, Amsterdam, The Netherlands) and DNA 136 
was extracted from the inter- and organic phase according to Tri Reagent
®
 RT manufacturer’s 137 
instructions. The bacterial load in the stomach was determined using a previously described H. 138 
suis specific quantitative real-time PCR (qPCR) [13]. 139 
2.5. Stomach cytokine responses 140 
The mRNA expression levels of IFN-γ, TNF-α, IL-4, IL-10 and IL-17 were assessed by RT-141 
qPCR using cDNA synthesized from stomach tissue as described previously [14]. The threshold 142 
cycle (Ct) values were normalized to the geometric mean of the Ct-values from the reference 143 
genes after which normalized mRNA levels were calculated using the 2
-∆ΔCt 
method [15]. 144 
2.6. Serum antibody responses 145 
Anti-rUreB, -rGGT and -lysate serum immunoglobulin G (IgG) responses were assessed by using 146 
the Protein Detector™ enzyme-linked immunosorbent assay (ELISA) Kit (KPL, Gaithersburg 147 
MD, USA). Measurement of anti-rUreB, anti- rGGT and -lysate specific serum IgG was 148 
performed as previously described [6]. In brief, 96 well flat bottom plates (Nunc MaxiSorp, 149 
Nalge Nunc Int., Rochester, NY, USA) were coated with 1 µg/well of purified rUreB, 2 µg/well 150 
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of purified rGGT, or 1 µg/well of H. suis whole cell proteins diluted in 100 µL coating buffer. 151 
After blocking with 1% bovine serum albumin in PBS, 100 µL of 1/400 diluted serum was added 152 
to each well. After further washing, 100 µL of HRP-labeled anti-mouse IgG (H+L) in a final 153 
concentration of 50 ng per well was added. Absorbance was read at 405nm (OD405nm). 154 
2.7. Histopathological examination 155 
Longitudinal strips of gastric tissue were fixed in 4% phosphate buffered formaldehyde, 156 
processed by standard procedures and embedded in paraffin. For evaluation of gastritis, 157 
haematoxylin - eosin (HE) stained sections of 5 µm were blindly scored based on the degree of 158 
infiltrating lymphocytes, plasma cells and neutrophils using a visual analog scale similar to the 159 
Updated Sydney System (on a scale of 0-3) [16] with additional specifications for each score. 160 
The inflammation scores used in the grading system were as follows: 0, no infiltration with 161 
mononuclear and/or polymorphonuclear cells; 1, mild diffuse infiltration with mononuclear 162 
and/or polymorphonuclear cells; 2, moderate diffuse infiltration with mononuclear and/or 163 
polymorphonuclear cells and/or the presence of one or two inflammatory aggregates; 3, marked 164 
diffuse infiltration with mononuclear and/or polymorphonuclear cells and/or the presence of at 165 
least three inflammatory aggregates.  166 
2.8. Statistical analysis 167 
Significant differences in H. suis colonization and mRNA cytokine expression among groups 168 
were assessed by performing one-way ANOVA analysis. Bonferroni’s multiple comparison test 169 
was used as post-hoc when equal variances were assessed. Dunnett’s T3 post-hoc test was used 170 
when no equal variances were assessed. OD405nm levels from ELISA were compared by Kruskall-171 
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Wallis analysis, followed by a Dunn’s multiple comparison test. Histological inflammation 172 
scores were compared using the Mann-Whitney U test. For correlations between different 173 
variables, Spearman’s rho coefficient (ρ) was calculated. GraphPad Prism5 software (GraphPad 174 
Software Inc., San Diego, CA) was used for all analyses. Statistically significant differences 175 
between groups were considered at p < 0.05. 176 
3. Results 177 
3.1. Protective effect of immunizations against H. suis challenge 178 
All immunizations induced a significant reduction of gastric bacterial load compared to sham-179 
immunized infected mice (p < 0.05), albeit significantly less pronounced in the group solely 180 
immunized with rGGT compared to all other immunizations (p < 0.01) (Figure 2). Highest levels 181 
of protection were seen in animals immunized with the combination of rGGT+rUreB or with 182 
lysate, with a 10 000-fold and 1000-fold reduction, respectively, of H. suis numbers (expressed as 183 
median) in the stomachs, compared to non-immunized infected controls (p < 0.001). Although 184 
not significant (p > 0.05), an enhanced protective effect was observed in mice immunized with 185 
combinations of rGGT and rUreB compared to rUreB alone. Immunization with rUreB alone, 186 
lysate, rGGT+rUreB and the subsequent immunization of rGGT followed by rUreB resulted in 187 
33%, 50%, 57% and 44% of mice negative for H. suis DNA, respectively. Immunization with 188 
rGGT alone did not result in mice negative for H. suis DNA in the stomach. During the study 14 189 
animals died, and the mortality rate per group is shown in Supplementary file 1. 190 
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           191 
Figure 2. Protection against H. suis challenge after prophylactic immunization. Bacterial 192 
load per mg stomach tissue was determined for individual mice in each group by qPCR and is 193 
illustrated as dots with indication of median (horizontal lines) and range (vertical lines). The 194 
dotted line (DL) designates the detection limit of 41.8 copies/mg stomach tissue.* p < 0.05, *** p 195 
< 0.001 compared to non-immunized (sham) H. suis-challenged mice. Immunized groups which 196 
differed significantly (p < 0.01) are marked with different letters. rGGT→rUreB: group of mice 197 
which were sequentially immunized with rGGT and rUreB. 198 
 199 
3.2. Stomach cytokine responses 200 
mRNA cytokine expression levels (IFN-γ, TNF-α, IL-4, IL-10 and IL-17) in gastric tissue are 201 
presented in Figure 3. Significantly higher levels of IL-17 and INF-γ were observed in animals 202 
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from all immunized groups, except in the group immunized with rGGT only, compared to sham-203 
immunized mice (p < 0.05). Increased levels of IL-17 and IFN-γ were significantly correlated 204 
with a decrease in bacterial load (p < 0.05, ρ = -0.513 and ρ = -0.2955, respectively). For IL-4, 205 
IL-10 and TNF-α no significant differences in mRNA expression levels were seen between 206 
groups after infection. However, mRNA expression levels of TNF- α were increased in all 207 
immunized groups, except in the group immunized with rGGT only, compared to non-immunized 208 
mice. In addition, a mild negative correlation was observed between gastric bacterial load and 209 
TNF-α expression levels (p < 0.05, ρ = -0.349). Lower levels of IL-10 were observed in 210 
immunized animals, compared to sham-immunized mice (p > 0.05) and a mild positive 211 
correlation was observed between gastric bacterial load and IL-10 expression levels (p < 0.05, ρ = 212 
0.356). 213 
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 214 
Figure 3. Fold change in cytokine gene expression levels in stomach tissue relative to 215 
negative control animals. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to non-immunized 216 
(sham) H. suis-challenged group. rGGT→rUreB: group of mice which were sequentially 217 
immunized with rGGT and rUreB. 218 
3.3. Humoral immune responses 219 
Three weeks after the last immunization, 1 week prior to challenge, specific serum anti-rUreB, 220 
anti-rGGT and anti-lysate IgG antibodies, were significantly increased in animals immunized 221 
with respective antigens compared to negative control mice (Supplementary file 2). Serum 222 
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antibody responses against H. suis lysate, rUreB and rGGT at euthanasia are shown in Figure 4. 223 
Negative controls and sham-immunized mice showed significantly lower anti-lysate, -rUreB and 224 
-rGGT serum IgG antibodies at euthanasia compared to groups vaccinated with lysate, -rUreB 225 
and/or -rGGT, respectively. A weak, but significant (p < 0.05, ρ = -0.235) correlation was 226 
observed between decreased bacterial load and increased specific serum IgG. 227 
 228 
Figure 4. Serum antibody responses against H. suis lysate (A), rUreB (B) and rGGT (C) at 229 
euthanasia. Different groups are indicated by the bars with levels of specific IgG shown as the 230 
mean OD405nm + SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant. rGGT→rUreB: 231 
group of mice which were sequentially immunized with rGGT and rUreB. 232 
 233 
3.4. Histopathology 234 
Figure 5 provides the results of histopathological examination of the stomachs. Higher 235 
inflammation scores were observed in the fundus compared to the antrum (Fig 5A and B). All 236 
negative controls had a normal gastric histomorphology (score 0) and sham-immunized, infected 237 
mice showed a weak gastric infiltration of mononuclear and/or polymorphonuclear cells (Fig 5C, 238 
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median score: 0.25). Most pronounced inflammation was observed in mice immunized with H. 239 
suis lysate (Fig 5C, median score: 1.125), followed by animals immunized with rUreB alone (Fig 240 
5C, median score: 1.00) and mice immunized with the bivalent vaccine of rGGT and rUreB (Fig 241 
5C, median score: 0.75). Immunization with rGGT alone and consecutive immunization of rGGT 242 
and rUreB resulted in less gastric infiltration of mononuclear and/or polymorphonuclear cells 243 
compared to all other immunizations, with a median score of 0.50 (Fig 5C). Inflammation in the 244 
fundic region and the average inflammation score of animals sequentially immunized with rGGT 245 
and rUreB were significantly lower compared to lysate-immunized mice (p = 0.0033 and p = 246 
0.0062, respectively). Lysate-immunized mice also showed significantly higher overall gastric 247 
inflammation and more severe inflammation in the fundic region compared to sham-immunized 248 
mice (p = 0.016 and p = 0.013, respectively). Average gastritis scores of H. suis-challenged 249 
groups immunized with lysate, rUreB, rGGT and rGGT+rUreB (simultaneously administered) 250 
differed significantly from that of non-infected negative control mice (p < 0.05). 251 
252 
Figure 5. (see legend on next page) 253 
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Figure 5. Gastric inflammation scores per group. Scores in negative controls, immunized 254 
and non-immunized (sham) mice 4 weeks after challenge were determined in fundus (A) 255 
and antrum (B) using haematoxylin-eosin-stained gastric sections. Average of inflammation 256 
score of fundus and antrum (average inflammation score) were calculated for each animal per 257 
group (C). 0, no infiltration with mononuclear and/or polymorphonuclear cells; 1, mild diffuse 258 
infiltration with mononuclear and/or polymorphonuclear cells; 2, moderate diffuse infiltration 259 
with mononuclear and/or polymorphonuclear cells and/or the presence of one or two 260 
inflammatory aggregates; 3, marked diffuse infiltration with mononuclear and/or 261 
polymorphonuclear cells and/or the presence of at least three inflammatory aggregates. Gastric 262 
scores of individual mice per group are illustrated as dots with indication of median (horizontal 263 
lines) and range (vertical lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to non-infected 264 
negative control group. a: significant difference in inflammation in fundic region between sham-265 
immunized and lysate-immunized mice, p = 0.013. b: significant difference in inflammation in 266 
fundic region between lysate-immunized mice and mice sequentially immunized with rGGT and 267 
rUreB (rGGT→rUreB), p = 0.0033. c: significant difference in average inflammation score 268 
between sham-immunized and lysate-immunized mice, p = 0.016. d: significant difference in 269 
average inflammation score between lysate-immunized mice and rGGT→rUreB immunized 270 
group, p = 0.0062. 271 
272 
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Discussion 273 
In a recent study, we demonstrated that intranasal vaccination with rUreB alone resulted in a 274 
significant reduction of gastric H. suis colonization, although complete protection was not 275 
achieved [6]. Therefore, the present study aimed to evaluate whether a combination of rUreB and 276 
rGGT could increase the vaccine efficacy. H. suis GGT is a secreted virulence factor that acts in a 277 
similar way as the H. pylori GGT. The enzyme causes a glutathione degradation-dependent 278 
epithelial cell death [10,17]. In addition, it inhibits the proliferation of T-cells and thus may 279 
prevent the generation of an effective host immune response [8,18]. 280 
Although immunization with rUreB or rGGT alone induced a significant reduction of gastric H. 281 
suis colonization, consecutive or simultaneous immunization with both antigens was more 282 
effective. The improved protective effect, of vaccination with combinations of rGGT and rUreB 283 
compared to immunization with rUreB only, may be related to the consistent anti-GGT response, 284 
which might overcome immune evasion induced by this enzyme, enhancing clearance of the 285 
bacteria after challenge. Vaccination with H. suis rGGT alone seems, however, to be less 286 
effective than vaccination with rUreB alone. 287 
H. suis colonization in mice generally induces a predominant Th17 response, in combination with 288 
a less pronounced Th2 response [14]. Despite this clear immune response, H. suis persists in 289 
infected mice. In contrast to H. pylori infection, H. suis infection does not result in increased 290 
levels of IFN-γ, a signature Th1 cytokine [14]. In the present study, vaccinated and protected 291 
mice showed significantly increased IFN-γ mRNA levels after challenge compared to sham-292 
immunized mice and the degree of protection was correlated with increased levels of IFN-γ. 293 
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Increased expression levels of the pro-inflammatory cytokine, TNF-α were also correlated with 294 
decreased bacterial gastric colonization. This indicates that a Th1 response may be involved in 295 
protective immunity against H. suis infection in mice. Indeed, we previously suggested that a 296 
combination of local Th17 and Th1 responses, complemented by antibody responses are involved 297 
in the protective immunity against H. suis infections [6]. Also in this study the degree of 298 
protection was correlated with increased levels of IL-17, a marker of Th17 response, and specific 299 
serum IgG responses. 300 
A decreased expression level of IL-10 was correlated with a reduction in gastric H. suis 301 
colonization. IL-10 is an anti-inflammatory cytokine, which is known to down-regulate immunity 302 
to infection and in this way may help gastric Helicobacter spp. to persist in their host [6,19,20]. 303 
In addition to IL-10, combined vaccination of rGGT and rUreB depicts reduced levels of IL-4. 304 
Although increased levels of pro-inflammatory cytokines (IFN-γ, TNF-α and IL-17) and a 305 
downregulation of IL-10 and IL-4 mRNA were observed in mice immunized with combinations 306 
of rGGT and rUreB, rather a decrease of the microscopic gastric lesions were observed. The 307 
reason for this seemingly contradictory result remains to be investigated. 308 
Ideally, an efficacious vaccine should induce protection whilst limiting side-effects. In 309 
prophylactic H. pylori mouse vaccination experiments, a more pronounced gastritis is often 310 
observed after challenging of immunized mice. This post-immunization gastritis is an important 311 
issue in the development of vaccines against H. pylori, especially when using whole-cell lysates 312 
[21-23]. In the present study, the severity of gastric inflammation was higher in mice immunized 313 
with whole-cell lysate compared to other immunizations and sham-immunized, infected mice. 314 
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Animals immunized first with rGGT followed by rUreB showed remarkably lower gastric 315 
inflammation compared to other immunized groups. The reason for this reduced inflammation is 316 
unclear and requires further studies. For example, the role of gastric and systemic cellular 317 
immune responses in induction and evolution of post-immunization gastritis may be determined 318 
by using CD4
+
-, B cell- or neutrophil deficient mice [24]. In addition, it has been shown that 319 
post-immunization gastritis disappears over time, indicating that it is a transient event [22,25]. A 320 
long term study could therefore be interesting to examine the evolution of the inflammatory 321 
response in all immunized, H. suis-challenged mice. 322 
The results obtained in our mouse model may also be relevant for pigs, which act as the natural 323 
host of H. suis. Further studies are, however, necessary to confirm this. From an anatomical 324 
point-of-view, the nasopharynx-associated lymphoid tissue (NALT) of pigs is organized as 325 
tonsils, and forms the basis of the Waldeyer’s ring [26], while NALT in rodents are presented as 326 
paired lymphoid aggregates in the floor of the nasal cavity at the entrance to the pharyngeal duct 327 
[27]. In rodents, lymphocytes from the nose preferentially home back to NALT, as well as 328 
cervical and mesenteric lymph nodes, but not to Peyer’s patches [28]. It is not clear whether this 329 
is also true for lymphocytes of the porcine NALT. Nevertheless, intranasal vaccination of pigs 330 
could be a promising route of vaccination for inducing protection not only at the local mucosa, 331 
but also at distant mucosal surfaces, as has been described for immunization against enteric 332 
colibacillosis [29]. 333 
In this study, an unexpected high mortality was observed in immunized groups that were 334 
experimentally infected with H. suis, within days after challenge. This was not observed in sham-335 
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immunized and negative control groups, indicating that this most likely relates to the combination 336 
of immunization and subsequent challenge. The exact cause of death, however, was unclear. An 337 
extensive local immune response after immunization and subsequent challenge with H. suis 338 
might be a possible cause of death. Based on autopsy results of some animals, a pronounced local 339 
immune response related to the administration route (intranasal) and the adjuvant (CT) after 340 
immunization and subsequent challenge, may lead to excessive swelling of the nasal cavity 341 
mucosae, resulting in oxygen deficiency. In future H. suis mouse vaccination experiments, it 342 
should therefore be evaluated whether other mucosal administration routes, such as sublingual or 343 
oral immunization, could lead to a similar degree of protection without increased mortality. 344 
 345 
In conclusion, immunization of mice with the combination of rGGT and rUreB, protected mice 346 
against a H. suis infection and induced less severe gastric lesions after H. suis challenge than 347 
immunization with a whole-cell vaccine. Both proteins are potential candidates for inclusion in 348 
subunit vaccines for control of H. suis infections. However, additional studies are needed to 349 
confirm the present results.  350 
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Supplementary files 437 
Supplementary file 1. Mortality rate in different groups during the study. 438 
 439 
 440 
 441 
 442 
 443 
 444 
Mice of groups 1, 2, 3 and 5 were intranasally immunized twice with rUreB, rGGT, 445 
rGGT+rUreB or lysate, respecitively. Groups 6 (sham-immunized group) and 7 (negative control 446 
group) were intranasally inoculated with HBSS. Mice from group 4 (rGGT→rUreB) were first 447 
intranasally immunized twice with 30 µg rGGT and 5 µg CT. One week after the second 448 
immunization animals were intranasally immunized twice with 30 µg rUreB and 5 µg CT. Four 449 
weeks after the last immunization, all animals, except the negative control group, were 450 
intragastrically inoculated 10
8
 viable H. suis bacteria. The negative control group was 451 
intragastrically inoculated with 200 µL Brucella broth at pH5. Four weeks after challenge with H. 452 
suis, mice were euthanized.
 
453 
a
Mice died 2 to 5 days after intragastric challenge with H. suis. 454 
Group Mortality rate (%) 
1. rUreB 40%
a
 
2. rGGT 20%
a
 
3. rGGT+rUreB 30%
a
 
4. rGGT→rUreB 10%
a
 
5. Lysate 40%
b
 
6. Sham-immunized 10%
c
 
7. Negative control 0% 
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b
Two mice died before challenge: one animal 5 days after the first immunization and one animal 455 
4 days after the second immunization. Two animals died 2 and 3 days after intragastric challenge 456 
with H. suis. 457 
c
One mouse was euthanized because of a reason unrelated to the study. 458 
 459 
Supplementary file 2. Serum antibody responses against H. suis lysate (A), rUreB (B) and rGGT 460 
(C) at three weeks after last immunization.  461 
 462 
Different groups are indicated by the bars with levels of specific IgG shown as the mean OD405nm 463 
+ SD. * p < 0.05, ** p < 0.01, ns: not significant. rGGT→rUreB: group of mice which were 464 
sequentially immunized with rGGT and rUreB. 465 
 466 
